EU and US sink teeth into "pay to delay" deals
This article was originally published in Scrip
Executive Summary
Originator and generics companies are coming under increasing scrutiny from regulators intent on rooting out suspected antitrust behaviour, with the European Commission and the US Federal Trade Commission both targeting deals that delay the entry of generic competition.